trending Market Intelligence /marketintelligence/en/news-insights/trending/3rxrtan_azolgy3skuz8-a2 content esgSubNav
In This List

EyePoint Pharmaceuticals elects new board chairman

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


EyePoint Pharmaceuticals elects new board chairman

EyePoint Pharmaceuticals Inc., a specialty biopharmaceutical company, elected Göran Ando to be the chairman of the company's board.

Ando was appointed to the board in June 2018, according to a Sept. 10 press release. He previously held positions with Pfizer Inc., held several senior appointments at GlaxoSmithKline PLC, and most recently served as the CEO for Celltech Group Ltd.

As part of the transition, David Mazzo will step down as the non-executive chairman but will remain on the board.